Evidence map›Paper›PMID 28075194›Full record

ArticleJournal of aerosol medicine and pulmonary drug delivery2017

Aerosol Drug Delivery During Noninvasive Positive Pressure Ventilation: Effects of Intersubject Variability and Excipient Enhanced Growth.

Ross L Walenga, P Worth Longest, Anubhav Kaviratna, Michael Hindle

Abstract readComparative Study
In one paragraph

Article in Journal of aerosol medicine and pulmonary drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Administration of dry powders during respiratory supports.Annals of translational medicine · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.Journal of aerosol medicine and pulmonary drug delivery · 2019
    Review
  13. Development of a High-Flow Nasal Cannula and Pharmaceutical Aerosol Combination Device.Journal of aerosol medicine and pulmonary drug delivery · 2019
    Article
  14. Article
  15. Review
  16. Article
  17. Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.Journal of aerosol medicine and pulmonary drug delivery · 2018
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ross L Walenga1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, Virginia.
P Worth Longest1 Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University , Richmond, Virginia.
Anubhav Kaviratna2 Department of Pharmaceutics, Virginia Commonwealth University , Richmond, Virginia.
Michael Hindle2 Department of Pharmaceutics, Virginia Commonwealth University , Richmond, Virginia.

Funding

High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept StudyR01HL107333 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI HINDLE, MICHAEL, LONGEST, P. WORTH · 2011 to 2020
$4.2M
NHLBI NIH HHS R01 HL107333
6 · The paper itself

Abstract

backgroundNebulized aerosol drug delivery during the administration of noninvasive positive pressure ventilation (NPPV) is commonly implemented. While studies have shown improved patient outcomes for this therapeutic approach, aerosol delivery efficiency is reported to be low with high variability in lung-deposited dose. Excipient enhanced growth (EEG) aerosol delivery is a newly proposed technique that may improve drug delivery efficiency and reduce intersubject aerosol delivery variability when coupled with NPPV. MATERIALS AND

methodsA combined approach using in vitro experiments and computational fluid dynamics (CFD) was used to characterize aerosol delivery efficiency during NPPV in two new nasal cavity models that include face mask interfaces. Mesh nebulizer and in-line dry powder inhaler (DPI) sources of conventional and EEG aerosols were both considered.

resultsBased on validated steady-state CFD predictions, EEG aerosol delivery improved lung penetration fraction (PF) values by factors ranging from 1.3 to 6.4 compared with conventional-sized aerosols. Furthermore, intersubject variability in lung PF was very high for conventional aerosol sizes (relative differences between subjects in the range of 54.5%-134.3%) and was reduced by an order of magnitude with the EEG approach (relative differences between subjects in the range of 5.5%-17.4%). Realistic in vitro experiments of cyclic NPPV demonstrated similar trends in lung delivery to those observed with the steady-state simulations, but with lower lung delivery efficiencies. Reaching the lung delivery efficiencies reported with the steady-state simulations of 80%-90% will require synchronization of aerosol administration during inspiration and reducing the size of the EEG aerosol delivery unit.

conclusionsThe EEG approach enabled high-efficiency lung delivery of aerosols administered during NPPV and reduced intersubject aerosol delivery variability by an order of magnitude. Use of an in-line DPI device that connects to the NPPV mask appears to be a convenient method to rapidly administer an EEG aerosol and synchronize the delivery with inspiration.

Indexed as

Drug Delivery SystemsPositive-Pressure RespirationAdultAerosolsDry Powder InhalersExcipientsFemaleHumansHydrodynamicsLungMasksModels, AnatomicNasal CavityNebulizers and VaporizersNoninvasive VentilationYoung AdultAerosolsExcipientscomputational fluid dynamicsexcipient enhanced growthinline dry powder inhalernebulized aerosolnoninvasive positive pressure ventilation

Identifiers

PMID28075194
PMCPMC5467151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.